Article and Video CATEGORIES
Dr. Duma is an Assistant Professor and Thoracic Oncologist at @UWcarbone and Former Chief Fellow @MayoClinic in Rochester, Minnesota. In addition to her dedication to her patients as a provider, Dr. Duma is committed to her research and advocacy in diversity and inclusion. She was recognized as the 2018 resident of the year by the National Hispanic Medical Association.
Telemedicina y telesalud: cómo COVID 19 ha transformado la atención del cáncer
En este video de discusión, el Dr. Narjust Duma habla con los Dres. Idalid "Ivy" Franco (Programa de Oncología Radioterápica de Harvard), Ana Velázquez Manana (Centro Integral de Cáncer Familiar Helen Diller de UCSF) y Luis Raez (Jefe de Hematología / Oncología y Director Médico - Memorial Cancer Institute).
Para este video, los médicos analizan el COVID-19 y los cambios actuales en la telemedicina, y comparten recomendaciones para los pacientes con cáncer durante la pandemia.
*****
Telemedicine and Telehealth - How COVID 19 has Transformed Cancer Care Covid and Cancer in the Latino Community
In this video discussion, Dr. Narjust Duma speaks with Drs. Idalid "Ivy" Franco (Harvard Radiation Oncology Program), Ana Velazquez Manana (UCSF Helen Diller Family Comprehensive Cancer Center) and Luis Raez (Chief Hematology/Oncology and Medical Director - Memorial Cancer Institute). For this video, the doctors discuss COVID-19 and the current changes in telemedicine, and share recommendations for patients with cancer during the pandemic.
To join the conversation, visit https://cancergrace.org/forum.
Para unirse a la conversación, visite https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…